Digital Therapeutics in Cardiovascular Healthcare: A Narrative Review

The rapid development of digital therapeutics (DTx) presents opportunities for cardiovascular diseases (CVD) intervention. This review aims to summarize the technologies and applications of DTx in the field of cardiovascular healthcare. It seeks to identify how DTx can enhance the effectiveness and efficiency of cardiovascular healthcare

Given the absence of a universally accepted definition, this review categorizes DTx applications in CVD into three main areas with based on widely recognized DTx characteristics: extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management

extended reality (XR)-assisted therapeutics, digital pill systems (DPS), and evidence-based applications designed for smartphones or smartwatches. XR aids surgical planning and execution by creating anatomical digital twins and providing immersive environments to reduce patient anxiety. DPS leverages ingestible sensors to enhance medication adherence and monitor physiological data, while APPs focus on CVD prevention, cardiac rehabilitation, and symptom tracking. Integrating artificial intelligence into DTx enhances its potential, allowing personalized interventions and improved data analysis. Despite its promise, the field faces challenges such as high costs, technological accessibility, and the need for robust regulatory frameworks to ensure safety and efficacy. With continued technological innovation and improved access, DTx is expected to play a transformative role in cardiovascular healthcare, bridging gaps in prevention, treatment, and long-term management.

DTx show promise in the prevention, intervention, and management of CVD. Despite existing challenges, technological advancements and regulatory improvements are expected to expand the role of DTx in cardiovascular healthcare.